Published on : Aug 12, 2016
ALBANY, New York, August, 12, 2016 - Market Research Hub has highlighted the pipeline landscape of liposarcoma therapeutics in a new report added to its repository. The main purpose of the research is to provide an assessment of the various pipeline therapeutics for liposarcoma. The report defines liposarcoma and also describes various treatments and therapies to treat it. The report states that the combination of surgeries and radiation therapy will be beneficial for treating various types of liposarcoma and will thus rise in demand in the coming years.
The report talks about common types of liposarcoma, a rare type of cancer that occurs in fat cells present in any part of the body, commonly thighs. Commonly found in people aged between 40 and 60, liposarcoma has now become a global issue. Common types of liposarcoma include well-differentiated liposarcoma, myxoid, dedifferentiated, and pleomorphic liposarcoma. Even though there are many ways to treat liposarcoma, companies are focusing on introducing new therapies and treatments in the global market. The rising government funding for research and development activities for the discovery of new therapies is expected to propel the global market in the coming years.
The report, titled ‘Liposarcoma - Pipeline Review, H1 2016,’ highlights the pharmacological action of various therapeutics and their history of research and development activities. For a competitive analysis, the research has listed key companies operating in the market, focusing on their research and development efforts, adoption to changing trends, and their efforts to discover new therapeutics for liposarcoma. Cellceutix Corporation, Daiichi Sankyo Company, Ltd., Horizon Pharma Plc., Immune Design Corp., Karyopharm Therapeutics, Inc., Merck & Co., Inc., Novartis AG, and Pfizer Inc. are some of the key companies operating in the market for liposarcoma.
As per the findings of the report, the market for liposarcoma therapeutics is expected to benefit from the entry of new companies. With the entry of new players, the introduction of new therapeutics, surgeries, and therapeutics is likely. As key companies plan to acquire the new entrants, the market is expected to become more competitive in the near future, predict the analysts.
The analysts have conducted an assessment of liposarcoma therapeutics on the basis of molecule type, target, route of administration, and mechanism of action. Drugs such as CMB-305, efatutazone, everolimus, HDM-201, interferon gamma-1b, KM-3174, palbociclib, pazopanib hydrochloride, pembrolizumab, ribociclib succinate, and selinexor are studied in the report. With many new liposarcoma drugs in the pipeline, the market is expected to grow smoothly in the coming years.
Click here to get more info with TOC in a PDF Format: http://www.marketresearchhub.com/enquiry.php?type=S&repid=746172
In the report, the analysts have investigated 20 therapy areas and around 3,000 indications. Key companies are combining radiation therapy with a number of surgeries to introduce a new solution for treating liposarcoma. With such innovations and with the development of new technologies, the liposarcoma therapeutics pipeline is expected to expand in the coming years, thus benefiting the market.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org